Abstract
One potential outcome of investing in genomic medicine is the provision of tools for creating a more cost-effective health-care system. Partly with this aim in mind, Thailand has launched two genotyping initiatives: the Thai SNP Discovery Project and the Thai Centre for Excellence in Life Sciences Pharmacogenomics Project. Together, these projects will help Thailand understand the genomic diversity of its population and explore the role that this diversity has in drug response and disease susceptibility in its population. A major future challenge will be for Thailand to integrate genomic medicine in its relatively young universal health-care system.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Marsh, S., Van Booven, D. J. & McLeod, H. L. Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics 7, 625–631 (2006).
Stone, R. Mongkol na Songkhla interview. Thai health minister defends controversial drug-patent policy. Science 316, 1408 (2007).
Séguin, B., Hardy, B., Singer, P. A. & Daar, A. S. Genomic medicine and developing countries: creating a room of their own. Nature Rev. Genet. 9, 487–493 (2008).
Séguin, B., Hardy, B., Singer, P. A. & Daar, A.S. Human genomic variation initiatives in emerging economies and developing countries Nature Rev. Genet. 9 (Suppl), S3–S4 (2008).
Hughes, C. A. et al. Abacavir hypersensitivity reaction: an update. Ann. Pharmacother. 42, 387–396 (2008).
Hughes, A. R. et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5, 203–211 (2004).
Hughes, A. R. et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J. 11 March 2008 (doi: 10.1038/tpj.2008.3).
Sadiq, S. T. & Pakianathan, M. Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK. Sex. Transm. Infect. 83, 181–182 (2007).
Watson, M. E., Pimenta, J. M., Spreen, W. R. & Hernandez, J. E. HLA-B*5701 and abacavir hypersensitivity. Pharmacogenetics 14, 783–784 (2004); author reply 14, 784 (2004).
Rauch, A. et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis. 43, 99–102 (2006).
Zucman, D., Truchis, P., Majerholc, C., Stegman, S. & Caillat-Zucman, S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J. Acquir. Immune Defic. Syndr. 45, 1–3 (2007).
International Labour Office. A Technical Note to the Government: Financing Universal Health Care in Thailand. [online], (2004).
Phanuphak, N. et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med. 8, 357–366 (2007).
The Ministry of Public Health and The National Health Security Office Thailand. Facts and evidences on the 10 burning issues related to the government use of patents on three patented essential drugs in Thailand. [online], (2007).
Kiertiburanakul, S., Khongnorasat, S., Rattanasiri, S. & Sungkanuparph, S. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. J. Med. Assoc. Thai. 90, 237–243 (2007).
Stone, R. Indian Ocean tsunami. In the wake: looking for keys to posttraumatic stress. Science 310, 1605 (2005).
Séguin, B., Hardy, B., Singer, P. A. & Daar, A. S. Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN). Nature Rev. Genet. 9 (Suppl), S5–S9 (2008).
Becerril, A. Aprueba el Senado sanciones a quienes trasladen tejido humano fuera de México. La Journada [online], (2008).
[No authors listed]. Friendly cooperation agreement signed by Tsinghua Science Park and Thailand Science Park. Tsinghua Science Park [online], (2007).
Jayaraman, K. S. Database targets Parsi genes. Nature 446, 475 (2007).
Chantratita, W. in Maximize the Effectiveness of HIV-1 Treatment by Using Molecular Techniques, Bioinformatics, and Pharmacogenomics. 275 (Graphic Hut Co., Ltd, Bangkok, 2008).
Secretary's Advisory Committee on Genetics, Health, and Society. Realizing the potential of pharmacogenomics: opportunities and challenges. [online], (2008).
Intarakumnerd, P. & Chaminade, C. Strategy versus practice in innovation systems policy: the case of Thailand. Asian Journal of Technology Innovation 15, 197–213 (2007).
Ford, N., Wilson, D., Costa Chaves, G., Lotrowska, M. & Kijtiwatchakul, K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS 21 (Suppl 4), S21–S29 (2007).
Seim, L. Thailand: government issues compulsory licences for HIV/AIDS drugs. HIV AIDS Policy. Law. Rev. 12, 28–29 (2007).
Steinbrook, R. Thailand and the compulsory licensing of efavirenz. N. Engl. J. Med. 356, 544–546 (2007).
Supakankunti, S. et al. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand. Bull. World Health Organ. 79, 461–470 (2001).
Thorsteinsdottir, H., Quach, U., Daar, A. S. & Singer, P. A. Conclusions: promoting biotechnology innovation in developing countries. Nature Biotechnol. 22 (Suppl), DC48–DC52 (2004).
Frew, S. E. et al. India's health biotech sector at a crossroads. Nature Biotechnol. 25, 403–417 (2007).
Bowser, R. Race as a proxy for drug response: the dangers and challenges of ethnic drugs. DePaul Law Rev. 53, 1111–1126 (2004).
Burchard, E. G. et al. The importance of race and ethnic background in biomedical research and clinical practice. N. Engl. J. Med. 348, 1170–1175 (2003).
Lee, S. S. The ethical implications of stratifying by race in pharmacogenomics. Clin. Pharmacol. Ther. 81, 122–125 (2007).
Tang, H. Confronting ethnicity-specific disease risk. Nature Genet. 38, 13–15 (2006).
Risch, N., Burchard, E., Ziv, E. & Tang, H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol. 3, comment2007. 1–200712 (2002).
Séguin, B., Hardy, B., Singer, P. A. & Daar, A. S. Bidil: recontextualizing the race debate. Pharmacogenomics J. 8, 169–173 (2008).
Indian Genome Variation Consortium. Genetic landscape of the people of India: a canvas for disease gene exploration. J. Genet. 87, 3–20 (2008).
Mudur, G. S. Stamp on Tagore's India Genetic map blurs lines. The Telegraph (Calcutta, India) [online], (2008).
Boutayeb, A. The double burden of communicable and non-communicable diseases in developing countries. Trans. R. Soc. Trop. Med. Hyg. 100, 191–199 (2006).
Daar, A. S. et al. Grand challenges in chronic non-communicable diseases. Nature 450, 494–496 (2007).
Acknowledgements
We gratefully acknowledge M. Maliakkal for her contributions to this project. This project was funded by Genome Canada through the Ontario Genomics Institute. The McLaughlin–Rotman Centre for Global Health, Program on Life Sciences, Ethics and Policy is primarily supported by Genome Canada through the Ontario Genomics Institute, the Ontario Research Fund, and the Bill and Melinda Gates Foundation. Other matching partners are listed the McLaughlin–Rotman Centre for Global Health web site. A.S.D. and P.A.S. are supported by the McLaughlin Centre for Molecular Medicine. P.A.S. is supported by a Canadian Institutes of Health Research Distinguished Investigator award.
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
FURTHER INFORMATION
DNA Analysis for Human Health in the Post-Genomic Era, APEC
FAQs on compulsory licensing of pharmaceuticals, World Trade Organization
Issues Paper from DNA Analysis for Human Health in the Post-Genomic Era
McLaughlin–Rotman Centre for Global Health
National Biotechnology Policy Framework 2004–2009
Reverse Brain Drain Project, National Health Foundation
TCELS Pharmacogenomics Project
Thailand Centre of Excellence in Life Sciences (TCELS)
Rights and permissions
About this article
Cite this article
Séguin, B., Hardy, BJ., Singer, P. et al. Universal health care, genomic medicine and Thailand: investing in today and tomorrow. Nat Rev Genet 9 (Suppl 1), S14–S19 (2008). https://doi.org/10.1038/nrg2443
Issue Date:
DOI: https://doi.org/10.1038/nrg2443
This article is cited by
-
A Report on Ten Asia Pacific Countries on Current Status and Future Directions of the Genetic Counseling Profession: The Establishment of the Professional Society of Genetic Counselors in Asia
Journal of Genetic Counseling (2018)
-
From diversity to delivery: the case of the Indian Genome Variation initiative
Nature Reviews Genetics (2008)
-
The next steps for genomic medicine: challenges and opportunities for the developing world
Nature Reviews Genetics (2008)